Antibiotic Prescribing in Children Hospitalized With COVID-19 and Multisystem Inflammatory Syndrome in Spain: Prevalence, Trends, and Associated Factors

David Aguilera-Alonso,¹,²,³,⁴ Cristina Epalza,⁵,⁶,⁷,⁸ Francisco José Sanz-Santaeufemia,¹ Carlos Grasa,⁴,⁵,⁶ Sara Villanueva-Medina,¹ Susana Melendo Pérez,¹ Eloisa Cervantes Hernández,¹ María Urrutaviçayu-Martínez,¹ Rosa Pino,¹ Marisa Navarro Gómez,¹,²,³ Javier Pilar Orive,¹,² Ana González Zárato,¹,²,³ Paula Vidal Lana,¹ Raúl González Montero,¹ Sara Ruiz González,¹ Cristina Calve,¹ María Isabel Iglesias-Bouzas,¹ José Manuel Caro-Teller,¹ Sara Domínguez-Rodríguez,¹,⁴,⁵ Álvaro Ballesteros,¹,⁴ Juan Mesa,¹,⁵,⁶ Elena Cobos-Carrascosa,¹ Alfredo Tagarro,¹,⁴,⁵,⁶,⁷ Cinta Moraleda,¹,⁴,⁵,⁶ and EPICO-AEP Working Group

¹Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ²Unidad de Investigación Maternoinfantil Fundación Familia Alonso (UDIMIFFA), Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain; ³CIBER Enfermedades Infecciosas (CIBERINFECS), Instituto de Salud Carlos III, Madrid, Spain; ⁴Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain; ⁵Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Sanitaria Hospital 12 de Octubre (IMAS12), Madrid, Spain; ⁶Fundación para la Investigación Biomédica del Hospital 12 de Octubre, RITIP (Traslational Research Network in Pediatric Infectious Diseases), Madrid, Spain; ⁷Department of Pediatrics, Hospital Infantil Universitario Niño Jesús, Madrid, Spain; ⁸Pediatrics, Infectious and Tropical Diseases Department, Hospital Universitario La Paz, Instituto Investigación Hospital La Paz (IDIPaz), RITIP (Traslational Research Network in Pediatric Infectious Diseases), Madrid, Spain; ⁹Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitario Vall d’Hebron, Vall d’Hebron Research Institute, Barcelona, Spain; ¹⁰Department of Pediatrics, Hospital Virgen de la Arrixaca, Murcia, Spain; ¹¹Pediatrics Department, Complejo Hospitalario de Navarra, Pamplona, Spain; ¹²Pediatrics Department, Hospital Sant Joan de Déu (HSJD), Barcelona, Spain; ¹³Pediatric Critical Care Service, Hospital Universitario Cruces, Barakaldo, Spain; ¹⁴Pediatric Critical Care Group, BioCruces Health Research Institute, Barakaldo, Spain; ¹⁵Department of Pediatrics, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain; ¹⁶Universidad Europea, Madrid, Spain; ¹⁷Department of Pediatrics, Hospital Lozano Blesa, Zaragoza, Spain; ¹⁸Department of Pediatrics, Hospital Sant Joan d’Alacant, Alicante, Spain; ¹⁹Department of Pediatrics, Hospital Universitario Severo Ochoa, Madrid, Spain; ²⁰Pediatric Critical Care Unit, Hospital Infantil Universitario Niño Jesús, Madrid, Spain; ²¹Pediatric Critical Care Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; and ²²Department of Pharmacy, Hospital Universitario 12 de Octubre, Madrid, Spain

The COVID-19 pandemic has had a devastating impact on healthcare systems worldwide. In addition to the high morbidity and mortality associated with SARS-CoV-2 infection, resource prioritization has led to a reduction or interruption in activities related to antimicrobial stewardship programs (ASPs) [1, 2]. This effect has also been described in pediatric settings, with an increase in antibiotic prescribing [3].

While bacterial coinfections or secondary infections have been reported in only 7% to 8% of all patients with COVID-19 [4–6], antibiotic prescribing has been estimated to be 56.6% to 74.6% in different series, but lower in children than in adults (38.5% vs 83.4%) [7, 8]. The substantial difference between antibiotic use and bacterial infections highlights the potential antibiotic overuse in patients with COVID-19.

Specific data on children are scarce [9, 10]. Expanding our knowledge of antibiotic prescribing patterns in the COVID-19 pediatric population could help to develop and implement ASPs, leading to more judicious use of antibiotics. In the present study, the authors sought to analyze the antibiotic prescribing prevalence, risk factors, and trends, as well as bacterial coinfections and secondary infections, in children hospitalized with COVID-19 or multisystem inflammatory syndrome (MIS-C) related to SARS-CoV-2 in Spain.

METHODS

We conducted a multicenter, cohort study of patients < 18 years hospitalized from March 1, 2020, through March 31, 2021, with SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR), rapid antigen test, or fulfilling World Health Organization criteria for MIS-C. The study was conducted nationally across 76 Spanish hospitals included in the Epidemiological Study of Coronavirus in Children in Spain (EPICO-AEP). EPICO-AEP cohort has been previously described [11].

Study Definitions

The prevalence of antibiotic prescribing was considered as the proportion of patients receiving any systemic antibiotic during admission. The length of therapy (LOT) was defined as the number of days that a patient received systemic antibiotics.
During admission, using 100 patient days of admission as the denominator. Patients were classified according to 2 diagnoses: (1) acute COVID-19 (symptoms and/or signs of acute SARS-CoV-2 infection) and (2) MIS-C. After central review, bacterial infections were considered based on microbiological isolation (positive culture or PCR) and clinical relevance.

**Statistics**

Data are summarized as frequency and percentage for categorical variables and median and interquartile range (IQR) for continuous variables. The monthly percentage change (MPC) was estimated to characterize trends. We used Joinpoint regression modeling of MPC calculations with log-transformed data models to calculate trends in antibiotic prescribing. Categorical variables were compared with χ² or Fisher’s test, and continuous variables were compared with the Mann-Whitney test. To identify factors associated with the prescribing of systemic antibiotics in patients with COVID-19, all factors with a P-value < .05 in bivariate analysis were included in a multivariate logistic regression model. Laboratory blood results were not included in multivariate analysis because of the high number of patients without these tests. All calculated P-values were 2-sided and an alpha level of 0.05 was used for assessing significance. Data were analyzed using Joinpoint Regression software v4.9.0.0 (Surveillance Research Program, National Cancer Institute) and Stata v15 (StataCorp, College Station, TX).

**Ethics**

This study was approved by the ethics committees of Hospital 12 de Octubre (20/101) and the other participating centers.

**RESULTS**

A total of 640 children were hospitalized with COVID-19 (n = 505, 78.9%) or MIS-C (n = 135, 21.1%). The median age was 4.3 years (IQR: 0.2-11.3 years), and 367 (57.3%) were males. One hundred and twenty-six children (19.7%) were admitted to the pediatric intensive care unit (PICU); 34 (5.3%) required invasive mechanical ventilation and 59 (9.2%) required inotropic support. Eight (1.3%) patients died.

Bacterial coinfections or secondary infections were detected in 7.0% (45/640) of cases and were more frequent in patients with COVID-19 (8.2%, 42/505) than with MIS-C (2.2%, 3/135) (P = .020). Urinary tract infections were the most frequent bacterial infections (40.0%, 18/45), mostly by *Escherichia coli*, followed by bloodstream infections (31.1%, 14/45). Coagulase-negative staphylococci were the most prevalent cause of bacteremia (42.9%, 6/14), followed by *Staphylococcus aureus*, *Streptococcus pneumoniae*, and *Streptococcus mitis*, with 2 cases each. Bacterial infections and isolations are included in Supplementary Table S1. Clinical presentation of patients with COVID-19 and bacterial infection are summarized in Supplementary Table S2.

During admission, 347/640 (54.2%) patients received one or more systemic antibiotic, with a LOT of 38.7 days/100 patient-days and a median duration of 4.5 days (IQR: 2.5-7.5). Antibiotic prescribing was more common (P < .001) in patients with MIS-C (88.9%, 120/135) than with COVID-19 (45.0%, 227/505). Likewise, the LOT was longer for patients with MIS-C (43.4 days/100 patient days) than those with COVID-19 (36.4 days/100 patient-days) (P < .001), as was median antibiotic duration (8.5 days [IQR: 6.5-11.5] for MIS-C vs 3.5 days [IQR: 2.5-6.5] for COVID-19; P = .004). The most frequently prescribed antibiotic was cefotaxime/ceftriaxone (53.9%, 187/347), followed by azithromycin (26.5%, 92/347), and amoxicillin-clavulanate (18.4%, 64/347). The list of prescribed antibiotics according to diagnosis is included in Supplementary Figures S1-S3.

Changes in the prevalence of antibiotic prescribing among children hospitalized with COVID-19 are shown in Figure 1. There was a significant decline in the prescription of antibiotics in patients with COVID-19 along the study period (MPC: −5.5% [95% confidence interval (CI): −9.7, −1.0]; P = .021), and a similar trend was seen for antibiotics prescribed during the first 48 hours of admission (MPC: −5.1% [95% CI: −9.6, −0.4]; P = .004). Individual evaluation of antibiotics in patients with COVID-19 revealed a trend for a decline in azithromycin prescription (MPC: −10.8% [95% CI: −21.9, 1.7]; P = .081). The LOT in patients with COVID-19 showed a trend for a decrease (MPC: −6.1% [95% CI: −13.9, 2.4]; P = .139). There was also a slight but significant decline in the prescription of antibiotics in patients with MIS-C along the study period (MPC: −1.6% [95% CI: −3.1, −0.1]; P = .044), but the LOT remained stable (MPC: +4.0% [95% CI: −4.5, 13.3]; P = .330).

Factors associated with antibiotic prescribing in patients with COVID-19 in multivariate analysis (Figure 2) were: fever (adjusted odds ratio [aOR]: 3.66 [95% CI: 2.12, 6.31]; P < .001), lung infiltrates (aOR: 3.52 [95% CI: 2.08, 5.97]; P < .001), sepsis (aOR: 12.95 [95% CI: 1.20, 140.00]; P = .035), malignant neoplasm (aOR: 2.86 [95% CI: 1.18, 6.93]; P = .020), and hematologic disease (aOR: 3.22 [95% CI: 1.09, 9.51]; P = .034). Additionally, every additional year of age increased the odds of receiving antibiotics (aOR: 1.04 [95% CI: 1.00, 1.08]; P = .035).

**DISCUSSION**

To the best of our knowledge, this is the largest study analyzing antibiotic prescribing and concomitant bacterial infection in hospitalized children with COVID-19 or MIS-C. About half (54.2%) of all patients in our cohort received systemic antibiotics during admission, which is higher than that reported by Yock-Corrales et al [10] (24.5%; 243/990 children) in a Latin American cohort including both outpatients and inpatients. Our reported rate is lower than the 69% (415/601) described by...
Swann et al [9] in hospitalized children in the United Kingdom, perhaps because our study was longer term (until March 2021 vs July 2020), with increasing evidence of low bacterial coinfection in COVID-19. A higher rate has also been described in adults (55%-85%) [7, 8], which is likely explained by the greater severity of SARS-CoV-2 infection in adults than in children.

The severity of acute COVID-19 (eg, fever, lung infiltrates, and PICU admission) and MIS-C was the main reason for antibiotic prescription in our cohort, similar to other adult and pediatric studies [7, 10]. Increasing age has been related to higher antibiotic use in the general population [7] and is confirmed in our study in a pediatric population.

We observed a decline in antibiotic use in COVID-19 cases over time, as reported in adults [7], but not yet described in children [10]. Azithromycin showed the greatest decline in use, likely related to the lack of efficacy in trials [12]. Additionally, a trend toward a reduced LOT was observed in children with COVID-19 but not with MIS-C. Elevated inflammatory markers and the severe clinical presentation in MIS-C overlap with sepsis signs, so empiric antibiotics are usually initiated and later discontinued if MIS-C diagnosis is confirmed.

Notably, we confirm a low rate (7.0%) of bacterial coinfections or secondary infections, especially in MIS-C (2.2%), as described in the aforementioned Latin American cohort (1.3% globally and 0% in MIS-C [10]). Similar to this study, the children in our cohort presented with different bacterial infections when compared with adults, notably urinary tract infections, and all bloodstream infections were due to Gram-positive microorganisms, in contrast to a higher prevalence of Gram-negative bloodstream infections in adults [5, 6].

This considerable difference between the rate of bacterial infections and the prevalence of antibiotic prescribing, especially in MIS-C, underlines the need for a tailored approach to antibiotic use. Antibiotics are likely not needed in the large majority of pediatric admissions for COVID-19. In patients with suspected MIS-C, they can be administered initially after collecting cultures but can be discontinued after 48 to 72 hours of culture incubation if no bacteria are isolated and MIS-C diagnosis is confirmed [13].

Our study has some limitations, including its single-country design. However, a large number of hospitals were included. Also, we focused on hospitalized children, which likely have a higher antibiotic use than outpatients. Because of the nature of our data, we could not distinguish between bacterial coinfections and secondary infections. Further studies are needed to assess this in the pediatric population.

In conclusion, we confirm a high prevalence of antibiotic prescription and low bacterial coinfections or secondary infections in hospitalized children with COVID-19 or MIS-C. A decline in antibiotic use was observed during the first year of the pandemic, but the LOT remained unchanged for MIS-C. Efforts to enhance pediatric ASP actions during the COVID-19 pandemic are needed.

**Supplementary Data**

Supplementary materials are available at the *Journal of The Pediatric Infectious Diseases Society* online (http://jpids.oxfordjournals.org).
Notes

Acknowledgments. We thank Kenneth McCreath for the meaningful comments and suggestions on English writing. K.M. is a Scientific Editor funded by Universidad Europea de Madrid.

Financial support. This study was funded by the Instituto de Salud Carlos III (ISCIII) and the European Union–Fondos FEDER (project PI20/00095) and partially supported by a grant from the Spanish Society of Pediatrics. D.A.-A. is funded by the Spanish Ministry of Health/ISCIII and co-funded by Fondos FEDER (Contrato Río Hortega CM18/00100). C.G. is funded by the Spanish Ministry of Health/ISCIII and co-funded by Fondos FEDER (Contrato Río Hortega CM19/00015).

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Ansari S, Hays JP, Kemp A, et al. The potential impact of the COVID-19 pandemic on global antimicrobial and biocide resistance: an AMR Insights global perspective. JAC Antimicrob Resist 2021; 3:dlab038.
2. Rodríguez-Baño J, Rossolini GM, Schultz C, et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Trans R Soc Trop Med Hyg 2021;115:1122–9.
3. Velasco-Arnaiz E, López-Ramos MG, Simó-Neto S, et al. Pediatric antimicrobial stewardship in the COVID-19 outbreak. Infect Control Hosp Epidemiol 2021;42:642–4.
4. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020;26:1622–9.
5. Russell CD, Fairaird CI, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe 2021;2:e354–65.
6. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020;81:266–75.
7. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect 2021;27:520–31.
8. Vaughn VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with Coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis 2021;72:e533–41.
9. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020;370:m3249.
10. Yock-Correllas A, Lenz J, Ulloa-Gutiérrez R, et al. High rates of antibiotic prescriptions in children with COVID-19 or multisystem inflammatory syndrome: a multinational experience in 990 cases from Latin America. Acta Paediatr 2021;110:1902–10.
11. Dominguez-Rodriguez S, Villaverde S, Sanz-Santareuembila FJ, et al. A Bayesian model to predict COVID-19 severity in children. Pediatr Infect Dis J 2021;40:287–93.
12. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397:605–12.
13. Tamma PD, Miller MA, Cosgrove SE. Rethinking how antibiotics are prescribed: incorporating the 4 moments of antibiotic decision making into clinical practice. JAMA 2019;321:139–40.

Figure 2. Factors in children hospitalized with COVID-19 associated with antibiotic prescribing in bivariate analysis included in the multivariate analysis. The odds ratio axis is displayed on a logarithmic scale. Abbreviations: aOR, adjusted odds ratio; CPAP, continuous positive airway pressure; HFOT, high-flow oxygen therapy; PICU, pediatric intensive care unit.